Best Life Sciences Companies in Princeton, United States
The 85 best Life Sciences companies in Princeton, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Certara.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Princeton
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Certara Provider of a platform for in silico drug discovery and consulting services | $341M | 56 mo ago | 827 827 → 1,510 (+83%) | William Feehery CEO | WordPressApple iCloud MailMicrosoft 365+40 | 4 patents AI-powered real-time document assistance and ML-driven mechanistic biological modeling tools. | — |
| 2 | Advaxis Developer of immunotherapies for the treatment of cancer | $141M | 62 mo ago | 12 | Ken Berlin President | AMPSwiperCloudinary+4 | 393 patents Engineered Listeria bacterial vectors for peptide vaccine delivery and lyophilized formulations. | — |
| 3 | Celator Pharma Celator Pharmaceuticals - Improving Patient Outcomes in Cancer | $137M | 157 mo ago | 20 | Scott Jackson CEO | — | — | — |
| 4 | Sopherion Therapeutics Limited information available | $128M | 208 mo ago | 11 | — | — | — | — |
| 5 | Agile Therapeutics Developer of therapeutics for women healthcare | $124M | 28 mo ago | 19 | Al Altomari Chairman & CEO | — | 160 patents Personalized transdermal/dermal contraceptive drug delivery systems | — |
| 6 | Oyster Point Pharmaceuticals Developer of gene therapies to treat ophthalmological diseases | $122M | 87 mo ago | 303 | — | — | — | — |
| 7 | Hengrui Therapeutics Developer of small molecule based therapeutics for the treatment of cancer, metabolic, and autoimmune… | $100M | 120 mo ago | 12 | — | — | — | — |
| 8 | Omthera Pharmaceuticals Science-led biopharmaceutical company delivering life-changing medicines, redefining cancer care | $99M | 159 mo ago | 2 | Jerry Wisler ex-CEO & President | — | — | — |
| 9 | Barrier Therapeutics Develops topical drugs for dermatology disorders | $78M | 271 mo ago | 50 | Geert Cauwenbergh ex-President & CEO | — | — | — |
| 10 | KBP BioSciences Innovating therapies for unmet medical needs in hypertension, cardiorenal, and infectious diseases | $76M | 101 mo ago | 37 | — | BootstrapApache HTTP ServerjQuery UI+7 | — | — |
| 11 | Vyome Therapeutics Developer of therapeutics for the immuno-inflammatory conditions | $63M | 89 mo ago | 8 | Venkateswarlu Nelabhotla Co-Founder & CEO | Framer SitesReactPriority Hints+4 | — | — |
| 12 | Pharmasset Therapeutics for the treatment of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) | $44M | 259 mo ago | 82 | — | — | 326 patents Design and synthesis of fluorinated nucleoside analogs for antiviral therapeutics | — |
| 13 | ArrePath Developer of anti-infectives to address antimicrobial resistance (AMR) | $20M | 12 mo ago | 16 | — | WordPressMySQLPHP+15 | 5 patents Computational drug ranking and design of antibacterial small‑molecule therapeutics. | — |
| 14 | NovaFlux Technologies Innovating healthcare through advanced medical device technologies and infection control | $20M | 9 mo ago | — | Mohamed Labib Founder & CEO | WixSentryEnvoy+12 | 77 patents Polymer-based oral care cleaning agents and drug‑release devices for membrane therapies | — |
| 15 | Derma Sciences Developer of tissue regeneration and wound care products | $18M | 179 mo ago | 143 | — | — | — | — |
| 16 | Protega Pharmaceuticals Provider of specialty pharmaceutical company that focuses on responsible pain management | $16M | 14 mo ago | — | Stefan Aigner CEO | — | — | — |
| 17 | Kayothera Developer of enzyme therapy for cancer treatment | $14M | 15 mo ago | 2 | Mark Esposito Founder & CSO | — | 23 patents Design of heterocyclic aldehyde dehydrogenase inhibitor compounds for therapeutic use. | — |
| 18 | Soligenix Developer of small molecule therapeutics for rare disease therapies | $10M | 45 mo ago | 15 15 → 26 (+73%) | Christopher Schaber Chairman | WordPress Block EditorWordPressMySQL+18 | 191 patents Pharmaceutical formulations and vaccine manufacturing, focusing on peptide therapeutics and nanomedicines. | — |
| 19 | CoreLab Partners Clinical trials, medical image assessment, and cardiac safety solutions and services | $9M | 179 mo ago | 350 | — | — | — | — |
| 20 | Wellmedix Science-driven skincare solutions for fragile skin, promoting health and resilience | $8M | 126 mo ago | 5 | Avani Kanubaddi CEO | PageFlyCart FunctionalityShopify+28 | — | — |
| 21 | Grace Therapeutics Developer of intravenous nimodipine formulation for aneurysmal subarachnoid hemorrhage | $7M | 32 mo ago | — | Prashant Kohli CEO & Director | BootstrapApache HTTP ServerKlaro+11 | — | — |
| 22 | Microdermis Specialty company developing OTC products using proprietary amidermal dermatological delivery platfomr | $7M | 125 mo ago | 11 | Mac Sweeney CEO | — | 38 patents Antimicrobial topical formulations, notably povidone‑iodine and sporicidal compositions | — |
| 23 | Impliant Provider of spine arthroplasty solutions for motion preservation | $7M | 199 mo ago | — | Todd Potokar CEO | — | — | — |
| 24 | Adgero Biopharma Developer of photodynamic therapy for cutaneous metastatic breast cancer | $6M | 71 mo ago | 7 | — | — | — | — |
| 25 | Atux Iskay Developer of small molecule modulators of Protein Phosphatase 2A | $5M | 15 mo ago | — | Michael Ohlmeyer Founder | — | 20 patents Medicinal chemistry of diaryl‑substituted tetrahydropyran and methylene scaffolds for therapeutic agents | — |
| 26 | Signum Biosciences Developer of therapeutics for treating dermatology and inflammatory disorders | $4M | 112 mo ago | 24 | Gregory Stock Co-Founder & Director | Squarespace CommerceCart FunctionalitySquarespace+15 | 140 patents Plant-derived nutraceutical compounds and formulations for health and wellness applications. | — |
| 27 | Flyway Health Provider of AI agents for healthcare data analysis and strategy | $4M | 7 mo ago | — | Taylan Aydın Co-Founder & CTO | — | — | — |
| 28 | Abeille Pharmaceuticals Late-stage drug development company focusing on oncology and diabetes, with expertise in oral sustained… | $3M | 207 mo ago | — | Suresh Borsadia CEO & President | — | — | — |
| 29 | TDL Innovations Developer of device to treat malignant pleural effusion | $2M | 60 mo ago | — | Glenn Laub Co-Founder & CEO | — | 43 patents Minimally invasive therapeutic foams and steerable catheter systems for drug delivery and tissue sampling | — |
| 30 | Optimeos Developer of drug delivery solutions by using biologics, peptides and RNA to treat multiple diseases | $2M | 26 mo ago | 4 | Robert Prudhomme Co-Founder | — | — | 1 partnership |
| 31 | iQure Pharma Developer of therapeutics for neuropathic pain | $2M | 18 mo ago | 6 | Peter Schiemann Co-Founder & Member Board Of Directors | — | — | 1 launch |
| 32 | Cheers Manufacturer of dietary supplements to manage drinking side effects | $2M | 87 mo ago | 57 | — | WebflowCart FunctionalityRuby+27 | — | 1 internship |
| 33 | Origin Developer of drug delivery platform for skin and soft-tissue infections | $2M | 32 mo ago | 7 | — | — | 148 patents Medical nitric oxide generation and delivery devices for therapeutic and diagnostic applications | — |
| 34 | Brighton Biotech Small molecule drug and vaccines for CNS disorders & infectious diseases | $2M | 139 mo ago | — | — | — | — | — |
| 35 | Honed Provider of cellular diagnostic testing and personalized vitamins for optimized health | $2M | 82 mo ago | 2 | Courtney Smith Co-Founder | — | — | — |
| 36 | Nanocan Developer of therapeutic solutions for cancer treatment | $1M | 14 mo ago | 5 | Eric Broyles Founder & CEO | — | — | — |
| 37 | Sonnet BioTherapeutics Developer of immunotherapies for the treatment of cancer | $750K | 18 mo ago | 12 12 → 11 (-8%) | Pankaj Mohan Founder & CEO & Chairman
| Apache HTTP ServerAmazon Web ServicesjQuery+8 | 46 patents Engineered cytokine‑albumin fusion proteins for enhanced therapeutic biologics | — |
| 38 | Snowdon US-based, early-stage biopharma discovering and developing anti-thrombotics for CV disease | $500K | 187 mo ago | 1 | William Welsh Co-Founder | — | — | — |
| 39 | ZywieBio Therapeutics company focused on treating metabolic and neurodegenerative Lysosomal Storage Diseases | $500K | 218 mo ago | 46 | Robert Johnston CEO | — | — | — |
| 40 | Zena Therapeutics Developer of therapeutics to treat alcohol use disorder | $364K | 16 mo ago | 2 | — | — | — | 1 award |
| 41 | RizLab Health Developer of an AI-based device for complete blood count analysis | $250K | 56 mo ago | 4 | Shahriar Azizpour Co-Founder | — | — | — |
| 42 | Synsei Non-invasive device to measure fetal cardiology | $150K | 149 mo ago | — | William Braunlin Co-Founder | — | — | — |
Top 12 Life Sciences companies in Princeton
#1
Funding Raised · Princeton, New Jersey · founded 1988$19.7Mraised▾
Innovating healthcare through advanced medical device technologies and infection control. The company is dedicated to pioneering new solutions in healthcare, focusing on infection control and dialysis therapies. They develop and commercialize medical devices using Two-Phase Flow technology and micro-structured fluids. Their innovations include biofilm removal, dialyzer reprocessing, and drug delivery systems. The company aims to improve patient outcomes and reduce healthcare costs. They are involved in research and development, creating intellectual property and licensing technologies. Their work has applications in diverse surgical areas. They are committed to pushing boundaries and making a difference in the healthcare industry.
- Sep 2025Grant (prize money)—
- Feb 2025Grant (prize money)$3M
- Jan 2025Grant (prize money)—
- Mar 2023Grant (prize money)$2M
#2
Seed · Princeton, New Jersey · founded 2021 · 16 employees$20Mraised▾
Developer of anti-infectives to address antimicrobial resistance (AMR). The company leverages machine learning (ML) and an imaging-based drug discovery platform to develop a pipeline of new classes of antibiotics to address drug-resistant infections.
- Jun 2025Seed—
- Nov 2024Grant (prize money)$1.3M
- Mar 2022Seed$20M
#3
Series A · Princeton, New Jersey · founded 2025$4Mraised▾
Provider of AI agents for healthcare data analysis and strategy. The agents autonomously identify revenue opportunities and care gaps from claims data. The offering includes insights with specific healthcare providers, accounts, and payers. The agents provide a ready-to-present strategy with a clear business case. The platform offers specialized agents for HCP segmentation, patient journey mapping, and payer strategy.
- Nov 2025Series A$4M
#4
Series A · Princeton, New Jersey · founded 2018 · 2 employees$14Mraised▾
Developer of enzyme therapy for cancer treatment. The platform is developing technology that can inhibit the enzyme that is responsible for protecting the cancer cell. The platform uses two pathways that are inhibition of the cancer stress resistance pathway and the other is depletion of regulatory T cells.
- Mar 2025Grant (prize money)$398K
- Jul 2023Grant (prize money)—
- Jul 2023Series A$5.2M
- May 2023Grant (prize money)$337.6K
#5
Series B · Princeton, New Jersey · founded 2020$15.8Mraised▾
Provider of specialty pharmaceutical company that focuses on responsible pain management. It offers RoxyBond formulated with SentryBond technology,is a abuse-deterrent immediate-release oxycodone hydrochloride for opioid abuse deterrence and for treating pain.
- Apr 2025Series B$15.8M
#6
Funding Raised · Princeton, New Jersey · founded 2018$5.3Mraised▾
Developer of small molecule modulators of Protein Phosphatase 2A (PP2A). The company focuses on therapeutic areas including oncology, neurodegenerative disease, and respiratory disease. Its PP2A activators have senotherapeutic potential and are being developed to impact human health. It provides samples of PP2A activator compounds to academic researchers to foster collaborations and publications, particularly seeking researchers in aging and metabolic disease/diabetes.
- Mar 2025Grant (prize money)$2.5M
- Jun 2022Grant (prize money)$406.5K
- Sep 2020Grant (prize money)$2.1M
- Jul 2020Grant (prize money)$199.6K
#7
Acquired · Princeton, New Jersey · founded 1997 · 19 employees$124.1Mraised▾
Developer of therapeutics for women healthcare. It offers a low estrogen dose seven day transdermal contraceptive patch system that delivers a combination of levonorgestrel and ethinyl estradiol.
- Feb 2024Grant (prize money)$275K
- Mar 2019Post IPO$7.8M
- Dec 2015Grant (prize money)$6M
- Feb 2015Post IPO$20M
#8
Series A · Princeton, Maryland · founded 2020 · 5 employees$1.4Mraised▾
Developer of therapeutic solutions for cancer treatment. The company's proprietary platform is developing drugs for treating multiple therapeutic areas like pancreatic cancer, cervical cancer, lung cancer, and COVID-19, breast cancer, prostate cancer, liver cancer, and glioblastoma. It uses radiotherapy biomaterials (nanoparticle drones) as a drug-delivery platform that deliver different drug payloads including immunotherapy drugs, chemotherapy drugs, and phytomedicines.
- Mar 2025Grant (prize money)$399.7K
- Dec 2022Series A$5.1M
- May 2022Grant (prize money)$399.7K
- May 2022Grant (prize money)$400K
#9
Series A · Princeton, New Jersey · founded 2019 · 6 employees$2.1Mraised▾
Developer of therapeutics for neuropathic pain. The company's pipeline include iQ-007 a positive allosteric modulator for EAAT2 found in epilepsy, and iQ-008 acts on pain-relevant molecular targets Cav1.2 channel, Sodium ion channels, and TRPV1 receptor for neuropathic pain.
#10
Public · Princeton, New Jersey · founded 2008 · 827 employees$340.7Mraised▾
Provider of a platform for in silico drug discovery and consulting services. It has software solutions for molecular modeling and simulation, pharmacokinetic and pharmacodynamic simulation, clinical trial simulators, and scientific informatics. The company provides drug development consulting and medical writing services.
- Sep 2021Grant (prize money)—
- Jul 2021Post IPO$250M
- Jun 2021Grant (prize money)$851.9K
- Nov 2016Grant (prize money)$334.4K
#11
Public · Princeton, New Jersey · founded 2011 · 12 employees$750Kraised▾
Developer of immunotherapies for the treatment of cancer. The company has proprietary FHAB™ (Fully Human Albumin Binding) technology that empowers the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms. The company's lead compound is SON-1010 for solid tumors.
- Dec 2024Post IPO$3.9M
- Jul 2023Post IPO$2.2M
- Aug 2020Post IPO$10.5M
- May 2019Seed$750K
#12
Funding Raised · Princeton, New Jersey · founded 2021 · 2 employees$364.4Kraised▾
Developer of therapeutics to treat alcohol use disorder. It offers medicinal and natural products to create drugs for poly-substance abuse, anxiety disorders, alcohol, and substance use.
- Feb 2025Grant (prize money)$364.4K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Princeton researches in biotechnology
- Princeton University15
- The Princeton Festival1
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.